Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration

Shortening duration of direct-acting antiviral therapy for chronic hepatitis C could provide cost savings, reduce medication exposure, and foster adherence and treatment completion in special populations. The current analysis indicates that measuring hepatitis C virus at baseline and on days 7 and 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Goyal, Ashish, Churkin, Alex, Barash, Danny, Cotler, Scott J, Shlomai, Amir, Etzion, Ohad, Dahari, Harel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045946/
https://www.ncbi.nlm.nih.gov/pubmed/35493122
http://dx.doi.org/10.1093/ofid/ofac157
_version_ 1784695418536329216
author Goyal, Ashish
Churkin, Alex
Barash, Danny
Cotler, Scott J
Shlomai, Amir
Etzion, Ohad
Dahari, Harel
author_facet Goyal, Ashish
Churkin, Alex
Barash, Danny
Cotler, Scott J
Shlomai, Amir
Etzion, Ohad
Dahari, Harel
author_sort Goyal, Ashish
collection PubMed
description Shortening duration of direct-acting antiviral therapy for chronic hepatitis C could provide cost savings, reduce medication exposure, and foster adherence and treatment completion in special populations. The current analysis indicates that measuring hepatitis C virus at baseline and on days 7 and 14 of therapy can identify patients for shortening therapy duration.
format Online
Article
Text
id pubmed-9045946
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90459462022-04-28 Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration Goyal, Ashish Churkin, Alex Barash, Danny Cotler, Scott J Shlomai, Amir Etzion, Ohad Dahari, Harel Open Forum Infect Dis Brief Report Shortening duration of direct-acting antiviral therapy for chronic hepatitis C could provide cost savings, reduce medication exposure, and foster adherence and treatment completion in special populations. The current analysis indicates that measuring hepatitis C virus at baseline and on days 7 and 14 of therapy can identify patients for shortening therapy duration. Oxford University Press 2022-03-22 /pmc/articles/PMC9045946/ /pubmed/35493122 http://dx.doi.org/10.1093/ofid/ofac157 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Goyal, Ashish
Churkin, Alex
Barash, Danny
Cotler, Scott J
Shlomai, Amir
Etzion, Ohad
Dahari, Harel
Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration
title Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration
title_full Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration
title_fullStr Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration
title_full_unstemmed Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration
title_short Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration
title_sort modeling-based response-guided daa therapy for chronic hepatitis c to identify individuals for shortening treatment duration
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045946/
https://www.ncbi.nlm.nih.gov/pubmed/35493122
http://dx.doi.org/10.1093/ofid/ofac157
work_keys_str_mv AT goyalashish modelingbasedresponseguideddaatherapyforchronichepatitisctoidentifyindividualsforshorteningtreatmentduration
AT churkinalex modelingbasedresponseguideddaatherapyforchronichepatitisctoidentifyindividualsforshorteningtreatmentduration
AT barashdanny modelingbasedresponseguideddaatherapyforchronichepatitisctoidentifyindividualsforshorteningtreatmentduration
AT cotlerscottj modelingbasedresponseguideddaatherapyforchronichepatitisctoidentifyindividualsforshorteningtreatmentduration
AT shlomaiamir modelingbasedresponseguideddaatherapyforchronichepatitisctoidentifyindividualsforshorteningtreatmentduration
AT etzionohad modelingbasedresponseguideddaatherapyforchronichepatitisctoidentifyindividualsforshorteningtreatmentduration
AT dahariharel modelingbasedresponseguideddaatherapyforchronichepatitisctoidentifyindividualsforshorteningtreatmentduration

Ejemplares similares